Evidence map›Paper›PMID 39245791›Full record

ArticleFEBS letters2024

PIN1 is a novel interaction partner and a negative upstream regulator of the transcription factor NFIB.

Sinem Saritas Erdogan, Ahmet Erdal Yilmaz, Asli Kumbasar

Abstract read
In one paragraph

Article in FEBS letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Nuclear Factor I-B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sinem Saritas ErdoganDepartment of Molecular Biology and Genetics, Istanbul Technical University, Turkey.ORCID https://orcid.org/0000-0002-9529-0877
Ahmet Erdal YilmazDepartment of Molecular Biology and Genetics, Istanbul Technical University, Turkey.ORCID https://orcid.org/0009-0004-6202-2755
Asli KumbasarDepartment of Molecular Biology and Genetics, Istanbul Technical University, Turkey.ORCID https://orcid.org/0000-0001-8574-2756

Funding

Bilimsel Araştırma Projeleri Birimi, İstanbul Teknik Üniversitesi 34480Bilimsel Araştırma Projeleri Birimi, İstanbul Teknik Üniversitesi 38905Bilimsel Araştırma Projeleri Birimi, İstanbul Teknik Üniversitesi 41432Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 115Z524Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 120Z994
6 · The paper itself

Abstract

NFIB is a transcription factor of the Nuclear Factor One (NFI) family that is essential for embryonic development. Post-translational control of NFIB or its upstream regulators have not been well characterized. Here, we show that PIN1 binds NFIB in a phosphorylation-dependent manner, via its WW domain. PIN1 interacts with the well-conserved N-terminal domains of all NFIs. Moreover, PIN1 attenuates the transcriptional activity of NFIB; this attenuation requires substrate binding by PIN1 but not its isomerase activity. Paradoxically, we found stabilization of NFIB by PIN1. We propose that PIN1 represses NFIB function not by regulating its abundance but by inducing a conformational change. These results identify NFIB as a novel PIN1 target and posit a role for PIN1 in post-translational regulation of NFIB and other NFIs.

Indexed as

NFI Transcription FactorsNIMA-Interacting Peptidylprolyl IsomeraseProtein BindingAnimalsHEK293 CellsHumansPeptidylprolyl IsomerasePhosphorylationProtein StabilityWW DomainsNFI Transcription FactorsNIMA-Interacting Peptidylprolyl IsomerasePeptidylprolyl IsomerasePIN1 protein, humanNFIBPIN1post‐translational regulationprotein–protein interactionstranscription factor

Identifiers

PMID39245791
PMCPMC11627009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.